Aristides Capital’s Neurogene NGNE Stock Holding History

Aristides Capital’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-695	Closed	-$171K	–	214
2019 Q4	$171K	Buy	+695	New	+$69.2K	0.13%	186

Other funds holding NGNE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Aristides Capital's NGNE Position: Q1 2020 in Review

Aristides Capital sold out of Neurogene (NGNE) in Q1 2020, closing a stake of 695 shares — an estimated $171K sold.

Aristides Capital first reported a position in NGNE in Q4 2019 and held it in 1 quarter. The position peaked at $171K in Q4 2019. 60 funds tracked by Wall St. Rank hold NGNE as of Q1 2020.

Aristides Capital reported no remaining Neurogene position as of Q1 2020 after selling out during the quarter.
Aristides Capital sold 695 Neurogene shares in Q1 2020, an estimated $171K.
Aristides Capital first reported a position in Neurogene in Q4 2019 and held it in 1 quarter.
Aristides Capital's Neurogene position peaked at $171K in Q4 2019.
60 funds tracked by Wall St. Rank held Neurogene as of Q1 2020.

Based on Aristides Capital's 13F filing for Q1 2020, filed 15 May 2020.